Sekisui to Buy Genzyme’s Test-Drug Operations For $265 Million

Sekisui Chemical Co. agreed to buy Genzyme Corp.’s test-drug operations for $265 million, according to a statement to the Tokyo Stock Exchange today.

To contact the reporter on this story: Go Onomitsu in Tokyo at

To contact the editor responsible for this story: Kyung Bok Cho at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.